Vasoactive peptides with angiogenesis-regulating activity predict cancer risk in males

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 3, 2012, Pages 513-522

  Belting, Mattias ^a,b   Almgren, Peter ^a   Manjer, Jonas ^a,b   Hedblad, Bo ^a,b   Struck, Joachim ^c   Wang, Thomas J ^e,f,g   Bergmann, Andreas ^d   Melander, Olle ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c THERMO FISHER SCIENTIFIC   (Germany)

^d Waltraut Bergmann Foundation   (Germany)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^g FRAMINGHAM HEART STUDY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; PROADRENOMEDULLIN; VASOPRESSIN;

ADULT; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CARBOXY TERMINAL SEQUENCE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; KIDNEY CANCER; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SKIN CANCER; STOMACH CANCER; URINARY TRACT CANCER; UTERINE CERVIX CANCER; UTERUS CANCER;

ADRENOMEDULLIN; ADULT; AGED; ATRIAL NATRIURETIC FACTOR; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GLYCOPEPTIDES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; RISK FACTORS; SURVIVAL RATE; SWEDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84859402298     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0840     Document Type: Article

References (53)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
2. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49. (Pubitemid 351656458)
3. Fernandez-Sauze S, Delfino C, Mabrouk K, Dussert C, Chinot O, Martin PM, et al.Effects of adrenomedullin on endothelial cells in the multistep process of angiogenesis: involvement of CRLR/RAMP2 and CRLR/RAMP3 receptors. Int J Cancer 2004;108:797-804. (Pubitemid 38112605)
4. Martinez A. A new family of angiogenic factors. Cancer Lett 2006;236:157-63.
5. Miyashita K, Itoh H, Sawada N, Fukunaga Y, Sone M, Yamahara K, et al. Adrenomedullin promotes proliferation and migration of cultured endothelial cells. Hypertens Res 2003;26 Suppl:S93-8. (Pubitemid 36372322)
6. Nikitenko LL, Fox SB, Kehoe S, Rees MC, Bicknell R. Adrenomedullin and tumour angiogenesis. Br J Cancer 2006;94:1-7. (Pubitemid 43088532)
7. Nikitenko LL, Smith DM, Hague S, Wilson CR, Bicknell R, Rees MC. Adrenomedullin and the microvasculature. Trends Pharmacol Sci 2002;23:101-3. (Pubitemid 34185404)
8. Oehler MK, Hague S, Rees MC, Bicknell R. Adrenomedullin promotes formation of xenografted endometrial tumors by stimulation of autocrine growth and angiogenesis. Oncogene 2002;21:2815-21. (Pubitemid 34499378)
9. Ribatti D, Nico B, Spinazzi R, Vacca A, Nussdorfer GG. The role of adrenomedullin in angiogenesis. Peptides 2005;26:1670-5. (Pubitemid 41169764)
10. Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension 1992;19:753-7.
11. Li L, Galligan JJ, Fink GD, Chen AF. Vasopressin induces vascular superoxide via endothelin-1 in mineralocorticoid hypertension. Hypertension 2003;41:663-8. (Pubitemid 36314571)
12. Simon JS, Baum JS, Moore SA, Kasson BG. Arginine vasopressin stimulates protein synthesis but not proliferation of cultured vascular endothelial cells. J Cardiovasc Pharmacol 1995;25:368-75.
13. Tahara A, Saito M, Tsukada J, Ishii N, Tomura Y, Wada K, et al. Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells. Eur J Pharmacol 1999;368:89-94. (Pubitemid 29106418)
14. Xie Z, Gao M, Batra S, Koyama T. Remodeling of capillary network in left ventricular subendocardial tissues induced by intravenous vasopressin administration. Microcirculation 1997;4:261-6. (Pubitemid 127674009)
15. Hu RM, Levin ER, Pedram A, Frank HJ. Atrial natriuretic peptide inhibits the production and secretion of endothelin from cultured endothelial cells. Mediation through the C receptor. J Biol Chem 1992;267:17384-9.
16. Itoh H, Pratt RE, Ohno M, Dzau VJ. Atrial natriuretic polypeptide as a novel antigrowth factor of endothelial cells. Hypertension 1992;19:758-61.
17. Lara-Castillo N, Zandi S, Nakao S, Ito Y, Noda K, She H, et al. Atrial natriuretic peptide reduces vascular leakage and choroidal neovascularization. Am J Pathol 2009;175:2343-50.
18. Pedram A, Razandi M, Hu RM, Levin ER. Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J Biol Chem 1997;272:17097-103. (Pubitemid 27289818)
19. Pedram A, Razandi M, Levin ER. Natriuretic peptides suppress vascular endothelial cell growth factor signaling to angiogenesis. Endocrinology 2001;142:1578-86. (Pubitemid 32299687)
20. Vesely DL. Metabolic targets of cardiac hormones' therapeutic anticancer effects. Curr Pharm Des 16:1159-66.
21. Vesely DL. Atrial natriuretic peptides: anticancer agents. J Investig Med 2005;53:360-5. (Pubitemid 41814249)
22. Humar R, Zimmerli L, Battegay E. Angiogenesis and hypertension: an update. J Hum Hypertens 2009;23:773-82.
23. Jain RK. Lessons from multidisciplinary translational trials on antiangiogenic therapy of cancer. Nat Rev Cancer 2008;8:309-16. (Pubitemid 351430862)
24. Vilar J, Waeckel L, Bonnin P, Cochain C, Loinard C, Duriez M, et al. Chronic hypoxia-induced angiogenesis normalizes blood pressure in spontaneously hypertensive rats. Circ Res 2008;103:761-9.
25. Machnik A, Neuhofer W, Jantsch J, Dahlmann A, Tammela T, Machura K, et al. Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med 2009;15:545-52.
26. Minisymposium: The Malmo Diet and Cancer Study. Design, biological bank and biomarker programme. 23 October 1991, Malmo, Sweden. J Intern Med 1993;233:39-79.
27. Persson M, Berglund G, Nelson JJ, Hedblad B. Lp-PLA(2) activity and mass are associated with increased incidence of ischemic stroke A population-based cohort study from Malmo, Sweden. Atherosclerosis 2008;200:191-8.
28. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engstrom G, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009;302:49-57.
29. Fenske W, Stork S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab 2009;94:123-9.
30. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005;51:1823-9. (Pubitemid 41368172)
31. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52:112-9. (Pubitemid 43032474)
32. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004;50:234-6. (Pubitemid 38125732)
33. Di Serio F, Ruggieri V, Varraso L, De Sario R, Mastrorilli A, Pansini N. Analytical evaluation of the Dade Behring Dimension RxL automated N-Terminal proBNP (NT-proBNP) method and comparison with the Roche Elecsys 2010. Clin Chem Lab Med 2005;43:1263-73. (Pubitemid 41600680)
34. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005;352:2049-60. (Pubitemid 40664306)
35. Garne JP. Invasive breast cancer in Malmö 1961-1992-an epidemiological study. Malmö, Sweden: Lund University. 1996.
36. Welfare. TNBoHa. Cancer incidence in Sweden 1999. Stockholm, Sweden: The National Board of Health and Welfare, 2001. 2001.
37. Welfare TNBoHa. Cancer incidence in Sweden 1996. Stockholm, Sweden: The National Board of Health and Welfare, 1998. 1998.
38. Enhorning S, Struck J, Wirfalt E, Hedblad B, Morgenthaler NG, Melander O. Plasma copeptin, a unifying factor behind the metabolic syndrome. J Clin Endocrinol Metab 2011;96:1065-72.
39. Sieveking DP, Chow RW, Ng MK. Androgens, angiogenesis and cardiovascular regeneration. Curr Opin Endocrinol Diabetes Obes 2010;17:277-83.
40. Sieveking DP, Lim P, Chow RW, Dunn LL, Bao S, McGrath KC, et al. A sex-specific role for androgens in angiogenesis. J Exp Med 2010;207:345-52.
41. Ichikawa-Shindo Y, Sakurai T, Kamiyoshi A, Kawate H, Iinuma N, Yoshizawa T, et al. The GPCR modulator protein RAMP2 is essential for angiogenesis and vascular integrity. J Clin Invest 2008;118:29-39.
42. Shindo T, Kurihara Y, Nishimatsu H, Moriyama N, Kakoki M, Wang Y, et al. Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene. Circulation 2001;104:1964-71. (Pubitemid 32983242)
43. Iimuro S, Shindo T, Moriyama N, Amaki T, Niu P, Takeda N, et al. Angiogenic effects of adrenomedullin in ischemia and tumor growth. Circ Res 2004;95:415-23. (Pubitemid 39100460)
44. Miller MJ, Martinez A, Unsworth EJ, Thiele CJ, Moody TW, Elsasser T, et al. Adrenomedullin expression in human tumor cell lines. Its potential role as an autocrine growth factor. J Biol Chem 1996;271:23345-51. (Pubitemid 26314779)
45. Nakayama M, Takahashi K, Murakami O, Shirato K, Shibahara S. Induction of adrenomedullin by hypoxia and cobalt chloride in human colorectal carcinoma cells. Biochem Biophys Res Commun 1998;243:514-7. (Pubitemid 28414056)
46. Zudaire E, Martinez A, Cuttitta F. Adrenomedullin and cancer. Regul Pept 2003;112:175-83. (Pubitemid 36351615)
47. Ishikawa T, Chen J, Wang J, Okada F, Sugiyama T, Kobayashi T, et al. Adrenomedullin antagonist suppresses in vivo growth of human pancreatic cancer cells in SCID mice by suppressing angiogenesis. Oncogene 2003;22:1238-42. (Pubitemid 36363387)
48. Kaafarani I, Fernandez-Sauze S, Berenguer C, Chinot O, Delfino C, Dussert C, et al. Targeting adrenomedullin receptors with systemic delivery of neutralizing antibodies inhibits tumor angiogenesis and suppresses growth of human tumor xenografts in mice. FASEB J 2009;23:3424-35.
49. Kong X, Wang X, Xu W, Behera S, Hellermann G, Kumar A, et al. Natriuretic peptide receptor a as a novel anticancer target. Cancer Res 2008;68:249-56. (Pubitemid 351380126)
50. Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet 2009;41:348-53.
51. Saleem U, Khaleghi M, Morgenthaler NG, Bergmann A, Struck J, Mosley TH Jr., et al. Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab 2009;94:2558-64.
52. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004;109:594-600. (Pubitemid 38198866)
53. Vila G, Riedl M, Maier C, Struck J, Morgenthaler NG, Handisurya A, et al. Plasma MR-proADM correlates to BMI and decreases in relation to leptin after gastric bypass surgery. Obesity (Silver Spring) 2009;17:1184-8.